Comparative Pharmacology
Head-to-head clinical analysis: CONSENSI versus METHYCLOTHIAZIDE AND DESERPIDINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CONSENSI versus METHYCLOTHIAZIDE AND DESERPIDINE.
CONSENSI vs METHYCLOTHIAZIDE AND DESERPIDINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Consensi is a fixed-dose combination of amlodipine, a dihydropyridine calcium channel blocker, and celecoxib, a nonsteroidal anti-inflammatory drug (NSAID) that selectively inhibits cyclooxygenase-2 (COX-2). Amlodipine inhibits calcium ion influx across cardiac and vascular smooth muscle cells, leading to vasodilation and reduced blood pressure. Celecoxib inhibits prostaglandin synthesis via COX-2, reducing inflammation and pain.
Methyclothiazide is a thiazide diuretic that inhibits sodium reabsorption in the distal convoluted tubule, reducing plasma volume; deserpidine is a Rauwolfia alkaloid that depletes catecholamines from peripheral sympathetic nerve endings, lowering peripheral vascular resistance.
Adults: 0.25 mg/kg intravenously over 1 hour every 2 weeks.
One tablet (5 mg methyclothiazide / 0.25 mg deserpidine) orally once daily. Maximum dose: one tablet daily.
None Documented
None Documented
Terminal elimination half-life of 12-15 hours for parent drug and 18-24 hours for active metabolite, allowing once-daily dosing.
Methyclothiazide: terminal half-life 17-24 hours, permitting once-daily dosing. Deserpidine: 50-100 hours, allowing accumulation with repeated dosing.
Primarily renal (70-80% as unchanged drug and active metabolite desmethyl-consensi); biliary/fecal: 15-20%.
Methyclothiazide: primarily renal excretion (60-70% unchanged) via tubular secretion; Deserpidine: extensive hepatic metabolism, <1% excreted unchanged in urine, with metabolites excreted in urine (40%) and feces (60%).
Category C
Category C
Antihypertensive/NSAID Combination
Thiazide Diuretic and Antihypertensive